JP2011522892A - パーキンソン病緩和のためのラサギリン - Google Patents
パーキンソン病緩和のためのラサギリン Download PDFInfo
- Publication number
- JP2011522892A JP2011522892A JP2011513503A JP2011513503A JP2011522892A JP 2011522892 A JP2011522892 A JP 2011522892A JP 2011513503 A JP2011513503 A JP 2011513503A JP 2011513503 A JP2011513503 A JP 2011513503A JP 2011522892 A JP2011522892 A JP 2011522892A
- Authority
- JP
- Japan
- Prior art keywords
- rasagiline
- parkinson
- disease
- patient
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title claims abstract description 386
- 229960000245 rasagiline Drugs 0.000 title claims abstract description 380
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 260
- 238000000034 method Methods 0.000 claims abstract description 192
- 238000011282 treatment Methods 0.000 claims abstract description 137
- 150000003839 salts Chemical class 0.000 claims abstract description 135
- 239000000939 antiparkinson agent Substances 0.000 claims abstract description 32
- 230000000648 anti-parkinson Effects 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- 230000008717 functional decline Effects 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims description 75
- 208000024891 symptom Diseases 0.000 claims description 63
- 230000008859 change Effects 0.000 claims description 35
- 230000000977 initiatory effect Effects 0.000 claims description 26
- 206010016256 fatigue Diseases 0.000 claims description 25
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 16
- 229960003946 selegiline Drugs 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical group CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 10
- 206010034010 Parkinsonism Diseases 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- 229960001956 rasagiline mesylate Drugs 0.000 claims description 9
- -1 levodoba Chemical compound 0.000 claims description 7
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 6
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 6
- 229960003805 amantadine Drugs 0.000 claims description 6
- 229960004596 cabergoline Drugs 0.000 claims description 6
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 6
- 229960003337 entacapone Drugs 0.000 claims description 6
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 6
- 229960003089 pramipexole Drugs 0.000 claims description 6
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 6
- 229960001879 ropinirole Drugs 0.000 claims description 6
- 229960003179 rotigotine Drugs 0.000 claims description 6
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 6
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 6
- 229960004603 tolcapone Drugs 0.000 claims description 6
- 229960001081 benzatropine Drugs 0.000 claims description 5
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 5
- 229960002802 bromocriptine Drugs 0.000 claims description 5
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 5
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 37
- 201000010099 disease Diseases 0.000 abstract description 25
- 229940068196 placebo Drugs 0.000 description 66
- 239000000902 placebo Substances 0.000 description 66
- 230000003111 delayed effect Effects 0.000 description 40
- 238000004458 analytical method Methods 0.000 description 39
- 230000033001 locomotion Effects 0.000 description 32
- 229940079593 drug Drugs 0.000 description 24
- 239000003814 drug Substances 0.000 description 24
- 229940001133 rasagiline 1 mg Drugs 0.000 description 16
- 206010044565 Tremor Diseases 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 11
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 11
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 10
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 9
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 8
- ZOMSMJKLGFBRBS-UHFFFAOYSA-N bentazone Chemical compound C1=CC=C2NS(=O)(=O)N(C(C)C)C(=O)C2=C1 ZOMSMJKLGFBRBS-UHFFFAOYSA-N 0.000 description 8
- 238000007405 data analysis Methods 0.000 description 8
- 230000006866 deterioration Effects 0.000 description 8
- 230000000324 neuroprotective effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- QLMMOGWZCFQAPU-UHFFFAOYSA-N CGP-3466 Chemical compound C#CCN(C)CC1=CC2=CC=CC=C2OC2=CC=CC=C12 QLMMOGWZCFQAPU-UHFFFAOYSA-N 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 229960004502 levodopa Drugs 0.000 description 6
- 206010071390 Resting tremor Diseases 0.000 description 5
- 230000002567 autonomic effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000004112 neuroprotection Effects 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 206010030312 On and off phenomenon Diseases 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000005713 exacerbation Effects 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000013179 statistical model Methods 0.000 description 4
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000008921 facial expression Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000006104 Cytochrome P-450 CYP1A2 Inhibitors Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 241000546188 Hypericum Species 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- 208000032443 Masked facies Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 238000013145 classification model Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- SQAZQLMBEHYFJA-BTJKTKAUSA-N n-(benzo[b][1]benzoxepin-5-ylmethyl)-n-methylprop-2-yn-1-amine;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C#CCN(C)CC1=CC2=CC=CC=C2OC2=CC=CC=C12 SQAZQLMBEHYFJA-BTJKTKAUSA-N 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229940127230 sympathomimetic drug Drugs 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- PAXWQORCRCBOCU-LURJTMIESA-N 6-fluoro-L-dopa Chemical compound OC(=O)[C@@H](N)CC1=CC(O)=C(O)C=C1F PAXWQORCRCBOCU-LURJTMIESA-N 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 229940031774 azilect Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000021058 soft food Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13193608P | 2008-06-13 | 2008-06-13 | |
| US61/131,936 | 2008-06-13 | ||
| US18972408P | 2008-08-22 | 2008-08-22 | |
| US61/189,724 | 2008-08-22 | ||
| PCT/US2009/003528 WO2009151625A1 (en) | 2008-06-13 | 2009-06-12 | Rasagiline for parkinson's disease modification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014255148A Division JP2015096532A (ja) | 2008-06-13 | 2014-12-17 | パーキンソン病緩和のためのラサギリン |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2011522892A true JP2011522892A (ja) | 2011-08-04 |
Family
ID=41415378
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513503A Pending JP2011522892A (ja) | 2008-06-13 | 2009-06-12 | パーキンソン病緩和のためのラサギリン |
| JP2014255148A Pending JP2015096532A (ja) | 2008-06-13 | 2014-12-17 | パーキンソン病緩和のためのラサギリン |
| JP2016234976A Withdrawn JP2017081938A (ja) | 2008-06-13 | 2016-12-02 | パーキンソン病緩和のためのラサギリン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014255148A Pending JP2015096532A (ja) | 2008-06-13 | 2014-12-17 | パーキンソン病緩和のためのラサギリン |
| JP2016234976A Withdrawn JP2017081938A (ja) | 2008-06-13 | 2016-12-02 | パーキンソン病緩和のためのラサギリン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090312436A1 (enExample) |
| EP (2) | EP2296462A4 (enExample) |
| JP (3) | JP2011522892A (enExample) |
| CN (2) | CN102065687A (enExample) |
| AU (2) | AU2009258151A1 (enExample) |
| BR (1) | BRPI0909894A2 (enExample) |
| CA (1) | CA2727022A1 (enExample) |
| EA (1) | EA201170018A1 (enExample) |
| IL (1) | IL209131A0 (enExample) |
| MX (1) | MX2010013766A (enExample) |
| NZ (1) | NZ589445A (enExample) |
| WO (1) | WO2009151625A1 (enExample) |
| ZA (1) | ZA201008484B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014508758A (ja) * | 2011-02-23 | 2014-04-10 | ユニバルシテ ラバル | パーキンソン病を治療するためのシスタミン類似体 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006014973A2 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| JP5701485B2 (ja) * | 2006-02-21 | 2015-04-15 | テバ ファーマシューティカル インダストリーズ リミティド | 多系統萎縮症の治療のためのラサギリンの使用 |
| MX2008012781A (es) | 2006-04-03 | 2008-10-14 | Teva Pharma | Uso de rasagilina para el tratamiento de sindrome de piernas inquietas. |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| EP2234478A4 (en) * | 2008-01-11 | 2013-01-23 | Teva Pharma | RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| NZ589547A (en) * | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| DK2451771T3 (da) | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| CA2806737A1 (en) * | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| EP2603212A4 (en) * | 2010-07-27 | 2014-01-08 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER |
| MX2013004598A (es) * | 2010-10-26 | 2013-07-17 | Teva Pharma | Rasagilina enriquesida con deuterio. |
| EA201490756A1 (ru) * | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз, Лтд. | Разагилина цитрамид |
| AU2012323349A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-formyl-propargyl-aminoindan |
| BR112014008552A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-metil-propargilaminoindano |
| CA2882072A1 (en) | 2012-08-17 | 2014-02-20 | Teva Pharmaceutical Industries Ltd. | Parenteral formulations of rasagiline |
| WO2015153629A1 (en) * | 2014-04-01 | 2015-10-08 | Teva Pharmaceutical Industries Ltd. | Determination of single nucleotide polymorphisms useful to predict response for rasagiline |
| US10292947B2 (en) * | 2016-03-26 | 2019-05-21 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for N-propargylamine derivative |
| EP3606541A1 (en) * | 2017-04-05 | 2020-02-12 | Crestovo Holdings LLC | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| AU2019427489B2 (en) * | 2019-01-28 | 2025-03-13 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
| GB202109826D0 (en) * | 2021-07-07 | 2021-08-18 | Bial Portela & Ca Sa | Treatment regimens for early idiopathic parkinson's disease |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| CN1031995C (zh) * | 1991-01-02 | 1996-06-12 | 奥韦特有限公司 | N-炔丙基-1-氨基茚满的r-对映体的制法 |
| IL112819A (en) * | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| DE69738275T2 (de) * | 1996-12-18 | 2008-08-28 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| AU2002319615A1 (en) * | 2001-07-20 | 2003-03-03 | Mount Sinai School Of Medicine Of New York University | Methods for diagnosing and treating alzheimer's disease and parkinson's disease |
| KR100614862B1 (ko) * | 2001-12-28 | 2006-08-22 | 다케다 야쿠힌 고교 가부시키가이샤 | 배뇨 장애 예방제/치료제 |
| ES2588780T3 (es) * | 2002-11-15 | 2016-11-04 | Teva Pharmaceutical Industries Limited | Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| WO2006014973A2 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| CA2901244A1 (en) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| US7491847B2 (en) * | 2005-11-17 | 2009-02-17 | Teva Pharmaceutical Industries, Ltd. | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) * | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| JP5701485B2 (ja) * | 2006-02-21 | 2015-04-15 | テバ ファーマシューティカル インダストリーズ リミティド | 多系統萎縮症の治療のためのラサギリンの使用 |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| MX2008012781A (es) * | 2006-04-03 | 2008-10-14 | Teva Pharma | Uso de rasagilina para el tratamiento de sindrome de piernas inquietas. |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| PT2101569E (pt) * | 2006-12-14 | 2012-01-13 | Teva Pharma | Base de rasagilina sólida cristalina |
| NZ577623A (en) * | 2006-12-14 | 2011-05-27 | Teva Pharma | Tannate salt of rasagiline |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| WO2009032202A1 (en) * | 2007-08-29 | 2009-03-12 | Nuon Therapeutics, Inc. | Treatment of brain disorders |
| US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| EP2234478A4 (en) * | 2008-01-11 | 2013-01-23 | Teva Pharma | RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| NZ589547A (en) * | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
| DE102008064061A1 (de) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| EP2485722A1 (en) * | 2009-10-09 | 2012-08-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of progressive supranuclear palsy |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
-
2009
- 2009-06-12 CN CN2009801230031A patent/CN102065687A/zh active Pending
- 2009-06-12 JP JP2011513503A patent/JP2011522892A/ja active Pending
- 2009-06-12 CN CN201310714021.5A patent/CN103893160A/zh active Pending
- 2009-06-12 EA EA201170018A patent/EA201170018A1/ru unknown
- 2009-06-12 EP EP09762921A patent/EP2296462A4/en not_active Withdrawn
- 2009-06-12 NZ NZ589445A patent/NZ589445A/xx unknown
- 2009-06-12 US US12/456,166 patent/US20090312436A1/en not_active Abandoned
- 2009-06-12 EP EP20130176166 patent/EP2666356A1/en not_active Withdrawn
- 2009-06-12 AU AU2009258151A patent/AU2009258151A1/en not_active Abandoned
- 2009-06-12 BR BRPI0909894-1A patent/BRPI0909894A2/pt not_active IP Right Cessation
- 2009-06-12 CA CA2727022A patent/CA2727022A1/en not_active Abandoned
- 2009-06-12 MX MX2010013766A patent/MX2010013766A/es not_active Application Discontinuation
- 2009-06-12 WO PCT/US2009/003528 patent/WO2009151625A1/en not_active Ceased
-
2010
- 2010-11-04 IL IL209131A patent/IL209131A0/en unknown
- 2010-11-25 ZA ZA2010/08484A patent/ZA201008484B/en unknown
-
2013
- 2013-11-27 US US14/092,526 patent/US20140243418A1/en not_active Abandoned
-
2014
- 2014-12-17 JP JP2014255148A patent/JP2015096532A/ja active Pending
-
2016
- 2016-11-15 AU AU2016259315A patent/AU2016259315A1/en not_active Abandoned
- 2016-12-02 JP JP2016234976A patent/JP2017081938A/ja not_active Withdrawn
Non-Patent Citations (4)
| Title |
|---|
| JPN6013056741; 永井将弘ら: '今後出てくる新しい治療法' Ｐｈａｒｍａ Ｍｅｄｉｃａ Ｖｏｌ．２４、Ｎｏ．９, 2006, ｐ．５７-６０ * |
| JPN6013056744; 長谷川一子: 'パーキンソン病では、薬物治療を早期に始めるほうが、病状進行を遅くすることができるのか？' 治療 Ｖｏｌ．８８、増刊号, 2006, ｐ．１１０７-１１１１ * |
| JPN6013056747; Ｐａｒｋｉｎｓｏｎ Ｓｔｕｄｙ Ｇｒｏｕｐ: 'Ａ Ｃｏｎｔｒｏｌｌｅｄ， Ｒａｎｄｏｍｉｚｅｄ， Ｄｅｌａｙｅｄ-Ｓｔａｒｔ Ｓｔｕｄｙ ｏｆ Ｒａｓａｇｉｌｉｎｅ ｉｎ Ｅａｒｌｙ Ｐａｒｋｉｎｓｏｎ Ｄｉｓｅａｓｅ' Ａｒｃｈ Ｎｅｕｒｏｌ Ｖｏｌ．６１, 2004, ｐ．５６１-５６６ * |
| JPN6013056751; Ｖ．Ｏｌｄｆｉｅｌｄ ｅｔ．ａｌ．: 'Ｒａｓａｇｉｌｉｎｅ' Ｄｒｕｇｓ Ｖｏｌ．６７, 2007, ｐ．１７２５-１７４７ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014508758A (ja) * | 2011-02-23 | 2014-04-10 | ユニバルシテ ラバル | パーキンソン病を治療するためのシスタミン類似体 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016259315A1 (en) | 2016-12-01 |
| EA201170018A1 (ru) | 2011-08-30 |
| NZ589445A (en) | 2013-06-28 |
| US20090312436A1 (en) | 2009-12-17 |
| BRPI0909894A2 (pt) | 2015-07-28 |
| JP2017081938A (ja) | 2017-05-18 |
| CN103893160A (zh) | 2014-07-02 |
| WO2009151625A1 (en) | 2009-12-17 |
| EP2666356A1 (en) | 2013-11-27 |
| MX2010013766A (es) | 2011-03-15 |
| US20140243418A1 (en) | 2014-08-28 |
| AU2009258151A1 (en) | 2009-12-17 |
| EP2296462A1 (en) | 2011-03-23 |
| JP2015096532A (ja) | 2015-05-21 |
| EP2296462A4 (en) | 2011-06-15 |
| CA2727022A1 (en) | 2009-12-17 |
| CN102065687A (zh) | 2011-05-18 |
| ZA201008484B (en) | 2012-05-30 |
| IL209131A0 (en) | 2011-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017081938A (ja) | パーキンソン病緩和のためのラサギリン | |
| Amsterdam | A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder | |
| Roth et al. | Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia | |
| Seppi et al. | The Movement Disorder Society evidence‐based medicine review update: treatments for the non‐motor symptoms of Parkinson's disease | |
| Kornstein et al. | Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies | |
| US20110130466A1 (en) | Use of rasagiline for the treatment of progressive supranuclear palsy | |
| Reimherr et al. | A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients | |
| JP2017531683A5 (enExample) | ||
| Coelho et al. | Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients | |
| Winkelman et al. | Current patterns and future directions in the treatment of insomnia | |
| KR20250034521A (ko) | 실조증을 치료하기 위한 릴루졸 전구약물의 용도 | |
| Roth et al. | The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study | |
| US20230270738A1 (en) | Methods of treating agitation associated with alzheimer's disease | |
| Thorpy | Sodium oxybate for the treatment of narcolepsy | |
| WO2024216061A1 (en) | Methods of treating depression and anhedonia | |
| WO2024216046A1 (en) | Methods of treating anhedonia | |
| Vakhapova et al. | Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety | |
| Isaacson et al. | Improving symptom control in early Parkinson’s disease | |
| Kennedy et al. | P. 2. c. 013 Antidepressant efficacy of agomelatine 25-50 mg versus venlafaxine 75-150 mg: two randomized, double blind studies | |
| Zesiewicz et al. | Medical treatment of motor and nonmotor features of Parkinson's disease | |
| US20180369421A1 (en) | Method for reducing the placebo effect in clinical trials | |
| Pretzer-Aboff et al. | The implications of Parkinson's disease for women's health | |
| HK1192112A (en) | Rasagiline for parkinson's disease modification | |
| AU2024238367A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| WO2025250535A1 (en) | Methods of treating depression and anhedonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131119 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140213 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140519 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140909 |